The DOI matches its Crossref record.
MM-464 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with triple-class-exposed relapsed and refractory multiple myeloma, conventional therapies yield poor prognosis, with median progression-free survival of approximately 3 to 5 months and median overall survival of approximately 9 to 22 months.
“Prognosis is poor with conventional therapies, with a median progression-free survival (PFS) of ~3 to 5 months and a median overall survival (OS) of ~9 to 22 months in this patient population. 5-12”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [12]
The median overall survival in both arms was substantially longer than historical real-world data in TCE R/RMM (~9-22 months).
“The median OS in the ide-cel (41.4 months) and SRs arms (37.9 months) were substantially longer than historical real-world data in TCE R/RMM (~9-22 months), 512 with longer than expected OS in the SRs arm, likely resulting from ide-cel treatment in patients who crossed over.”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood · doi:10.1182/blood.2024024582 · Cited by 79
Self-citation
Metadata
- Authors
- Moreau, P., Weisel, K., de Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Vincent, L., Perrot, A., Benjamin, R., van de Donk, N., Ocio, E., Groen-Damen, E. I. ‘., Roccia, T., Schecter, J., Haddad, I., Strulev, V., Mitchell, L., Buyze, J., Saarinen, S., Filho, O. C., Einsele, H., & Mateos, M.-V.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Mayo Clinic (US)
- University Hospital Heidelberg (DE)
- Georgetown University Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Nottingham University Hospitals NHS Trust (GB)
- Poznan University of Medical Sciences (PL)
- Ospedale Policlinico San Martino (IT)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- King's College London (GB)
- Marqués de Valdecilla University Hospital (ES)
- Janssen Research & Development (United States) (US)
- Janssen (Belgium) (BE)
- Actelion (Switzerland) (CH)
- Legend Biotech (United States) (US)
- Universitätsklinikum Würzburg (DE)
- Complejo Hospitalario de Salamanca (ES)
- ORCID
- Venue
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 23
- Pages
- S500-S501
- ISSN
- 2152-2650 (ISSN-L)
- OpenAlex
- W4386271193
- Cited by
- 1
- References
- 0
- Citations by year
- 2024: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Clinical Lymphoma Myeloma & Leukemia (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- relapsed/refractory multiple myeloma, standard of care treatment, real-world treatment patterns, overall response rate, progression-free survival, overall survival, treatment duration, treatment safety, proteasome inhibitors, immunomodulators, last-line therapy, treatment discontinuation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
